Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the provision of therapeutics for chronic liver diseases and viral infections. The company is headquartered in South San Francisco, California and currently employs 70 full-time employees. The company went IPO on 2020-10-16. Its pipeline of drug candidates includes ALG-000184 for chronic HBV infection, ALG-055009 for MASH, ALG-097558 for coronavirus infections, and a portfolio of preclinical programs. ALG-000184 is a potential Capsid Assembly Modulator (CAM-E) for chronic HBV infection with enhanced pharmacologic properties. In the area of chronic HBV infection, its advanced drug candidate, ALG-000184, helps in disrupting the HBV lifecycle with viral suppression as well as reductions in viral antigens. Its ALG-055009 is an oral, small-molecule thyroid receptor beta agonist (THR-β) for the treatment of MASH.
Follow-Up Questions
What is Aligos Therapeutics Inc (ALGS)'s P/E Ratio?
The P/E ratio of Aligos Therapeutics Inc is N/A
Who is the CEO of Aligos Therapeutics Inc?
Dr. Lawrence Blatt is the Chairman of the Board of Aligos Therapeutics Inc, joining the firm since 2018.
What is the price performance of ALGS stock?
The current price of ALGS is 9.92, it has decreased 0.69% in the last trading day.
What are the primary business themes or industries for Aligos Therapeutics Inc?
Aligos Therapeutics Inc belongs to Biotechnology industry and the sector is Health Care
What is Aligos Therapeutics Inc market cap?
Aligos Therapeutics Inc's current market cap is $61
Is Aligos Therapeutics Inc a buy, sell, or hold?
According to wall street analysts, 6 analysts have made analyst ratings for Aligos Therapeutics Inc, including 3 strong buy, 6 buy, 1 hold, 0 sell, and 3 strong sell
